Viking's Post-Hip Fracture Drug Succeeds In Phase II, But Pivotal Endpoints Unclear
The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?
You may also be interested in...
The mid-stage company is approaching Phase II data read outs for two lead assets. It is looking to partner with larger pharmas, but is also pursuing orphan indications that it could develop independently.
Viking Therapeutics Inc. has clinical-stage compounds for disorders amplifying as the world's population ages. The start-up’s first drug candidate is a potential treatment for people recovering from hip fracture; the second shows promise for fatty liver disorders that are spreading as the western diet does.
Viking Therapeutics licensed five assets from Ligand Pharmaceuticals, including a clinical-stage type 2 diabetes program that the private San Diego-based company has been working on since it was founded in late 2012.